Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Reexamination Certificate
2001-08-13
2002-05-28
Reamer, James H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
C514S493000
Reexamination Certificate
active
06395774
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compositions for delivering active agents, and particularly biologically active agents. The carriers in these compositions facilitate the delivery of a cargo to a target. These delivery compositions are particularly useful in the oral delivery of biologically active agents such as pharmacologically or therapeutically active agents. Methods for the preparation and for the administration of such compositions are also disclosed.
BACKGROUND OF THE INVENTION
Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, or the target itself.
Biologically active agents are particularly vulnerable to such barriers. For example in the delivery to animals of pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target. Chemical barriers include, but are not limited to, pH variations, lipid bi-layers, and degrading enzymes.
These barriers are of particular significance in the design of oral delivery systems. Oral delivery of many biologically active agents would be the route of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastrointestinal (GI) tract, powerful digestive enzymes, and active agent impermeable gastro-intestinal membranes. Among the numerous agents which are not typically amenable to oral administration are biologically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastrointestinal tract by acid hydrolysis, enzymes, or the like.
Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.
Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Pat. No. 4,239,754; Patel et al. (1976),
FEBS Letters
, Vol. 62, pg. 60; and Hashimoto et al. (1979),
Endocrinology Japan
, Vol. 26, pg. 337.
However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.
More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example, U.S. Pat. No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.
There is still a need in the art for simple, inexpensive delivery systems which are easily prepared and which can delivery a broad range of active agents.
SUMMARY OF THE INVENTION
Compositions useful in the delivery of active agents are provided. These delivery compositions comprise (a) an active agent; and (b) a carrier comprising at least one mono-C-substituted or di-C-substituted diketopiperazine. Biologically active agents and pharmacologically active agents may be incorporated as the active agent, and these compositions may be in the form of microspheres.
Also contemplated is a method for preparing these compositions wherein at least one active agent is mixed with a carrier as described above or wherein the carrier is solubilized in a solvent, and the carrier solution is contacted with the active agent and a precipitator solution in which the carrier is insoluble.
In a further embodiment, the compositions are administered, preferably orally, to animals.
REFERENCES:
patent: 3976773 (1976-08-01), Curran et al.
patent: 4289759 (1981-09-01), Heavener
patent: 4613500 (1986-09-01), Suzuki
patent: 4757066 (1988-07-01), Shiokari et al.
patent: 4835312 (1989-05-01), Itoh et al.
patent: 4873087 (1989-10-01), Morishita et al.
patent: 4900730 (1990-02-01), Miyauchi
patent: 4925673 (1990-05-01), Steiner
patent: 4927928 (1990-05-01), Shroot et al.
patent: 4983402 (1991-01-01), Steiner et al.
patent: 5244653 (1993-09-01), Berke et al.
patent: 5352461 (1994-10-01), Feldstein et al.
patent: 5401516 (1995-03-01), Milstein et al.
patent: 5443841 (1995-08-01), Milstein et al.
patent: 5447728 (1995-09-01), Milstein et al.
patent: 5451410 (1995-09-01), Milstein et al.
patent: 5541155 (1996-07-01), Leone-Bay et al.
patent: 5578323 (1996-11-01), Milstein et al.
patent: 5601846 (1997-02-01), Milstein et al.
patent: 5629020 (1997-05-01), Leone-Bay et al.
patent: 5643957 (1997-07-01), Leone-Bay et al.
patent: 5693338 (1997-12-01), Milstein
patent: 5714167 (1998-02-01), Milstein et al.
patent: 5766633 (1998-06-01), Milstein et al.
patent: RE35862 (1998-07-01), Steiner et al.
patent: 5792451 (1998-08-01), Sarubbi et al.
patent: 5811127 (1998-09-01), Milstein et al.
patent: 5824345 (1998-10-01), Milstein et al.
patent: 5840340 (1998-11-01), Milstein et al.
patent: 6331318 (2001-12-01), Milstein
patent: 2095994 (1982-10-01), None
International Search Report for PCT/US95/12887 (1996).
Gyore et al. Thermal Analysisi, vol. 2—Proceeding Fourth ICTA Budapest 1974; 387-394.
Chemical Abstracts, vol. No. 114(22), Ab-stract No. 214519x (1990).
Gurrieri and Siracusa: “Thermal Condensation of Some alpha-aminoacids with Phatalic Acid” Thermochimica Acta, 7 (1973) 231-239.
Darby & Darby
Emisphere Technologies Inc.
Reamer James H.
LandOfFree
Carbon-substituted diketopiperazine delivery systems does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbon-substituted diketopiperazine delivery systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbon-substituted diketopiperazine delivery systems will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2863323